🇺🇸 TRAMETINIB in United States

4,738 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Pyrexia — 1,244 reports (26.26%)
  2. Malignant Neoplasm Progression — 890 reports (18.78%)
  3. Product Use In Unapproved Indication — 382 reports (8.06%)
  4. Diarrhoea — 366 reports (7.72%)
  5. Rash — 330 reports (6.96%)
  6. Nausea — 329 reports (6.94%)
  7. Off Label Use — 314 reports (6.63%)
  8. Vomiting — 310 reports (6.54%)
  9. Fatigue — 299 reports (6.31%)
  10. Death — 274 reports (5.78%)

Source database →

TRAMETINIB in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is TRAMETINIB approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for TRAMETINIB in United States?

Marketing authorisation holder not available in our data.